[go: up one dir, main page]

WO2003011008A3 - Therapeutic delivery compositions and methods of use thereof - Google Patents

Therapeutic delivery compositions and methods of use thereof Download PDF

Info

Publication number
WO2003011008A3
WO2003011008A3 PCT/US2002/024425 US0224425W WO03011008A3 WO 2003011008 A3 WO2003011008 A3 WO 2003011008A3 US 0224425 W US0224425 W US 0224425W WO 03011008 A3 WO03011008 A3 WO 03011008A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
therapeutic delivery
delivery compositions
compositions
copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/024425
Other languages
French (fr)
Other versions
WO2003011008A2 (en
Inventor
Martin R Emanuele
Konstantin G Kousoulas
Hameedsulthan S Allaudeen
Mark Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CYRX Corp
Original Assignee
CYRX Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/919,504 external-priority patent/US20020123476A1/en
Priority claimed from US09/929,819 external-priority patent/US6933286B2/en
Application filed by CYRX Corp filed Critical CYRX Corp
Priority to US10/485,610 priority Critical patent/US20040248833A1/en
Priority to EP02765919A priority patent/EP1421170A2/en
Priority to JP2003516253A priority patent/JP2005500340A/en
Priority to CA002455843A priority patent/CA2455843A1/en
Publication of WO2003011008A2 publication Critical patent/WO2003011008A2/en
Anticipated expiration legal-status Critical
Publication of WO2003011008A3 publication Critical patent/WO2003011008A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of nucleic acid sequences. The methods and compositions rely on copolymers of polyethylene oxide and polypropylene oxide.
PCT/US2002/024425 1991-03-19 2002-07-31 Therapeutic delivery compositions and methods of use thereof Ceased WO2003011008A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/485,610 US20040248833A1 (en) 1991-03-19 2002-07-31 Therapeutic delivery compositions and methods of use thereof
EP02765919A EP1421170A2 (en) 2001-07-31 2002-07-31 Therapeutic delivery compositions and methods of use thereof
JP2003516253A JP2005500340A (en) 2001-07-31 2002-07-31 Composition for delivery for therapy and method of use thereof
CA002455843A CA2455843A1 (en) 2001-07-31 2002-07-31 Therapeutic delivery compositions and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/919,504 2001-07-31
US09/919,504 US20020123476A1 (en) 1991-03-19 2001-07-31 Therapeutic delivery compositions and methods of use thereof
US09/929,819 US6933286B2 (en) 1991-03-19 2001-08-14 Therapeutic delivery compositions and methods of use thereof
US09/929,819 2001-08-14

Publications (2)

Publication Number Publication Date
WO2003011008A2 WO2003011008A2 (en) 2003-02-13
WO2003011008A3 true WO2003011008A3 (en) 2004-03-25

Family

ID=27129773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024425 Ceased WO2003011008A2 (en) 1991-03-19 2002-07-31 Therapeutic delivery compositions and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1421170A2 (en)
JP (1) JP2005500340A (en)
CA (1) CA2455843A1 (en)
WO (1) WO2003011008A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902500A (en) * 1987-11-27 1990-02-20 Akzo N.V. Stabilization of antibodies
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5824322A (en) * 1995-08-21 1998-10-20 Cytrx Corporation Compositions and methods for growth promotion
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US4902500A (en) * 1987-11-27 1990-02-20 Akzo N.V. Stabilization of antibodies
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US5824322A (en) * 1995-08-21 1998-10-20 Cytrx Corporation Compositions and methods for growth promotion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] 1986, PAHLSON ET AL.: "Curved rods related to Mobiluncus: phenotypes as defined by monoclonal antibodies; hybridoma generation and monoclonal antibody production", XP002964700, accession no. STN Database accession no. 1986-10657 *
DATABASE MEDLINE [online] May 1989 (1989-05-01), WOODARD ET AL.: "Adjuvant activity of water insoluble surfactans", XP002964699, accession no. STN Database accession no. 89260215 *

Also Published As

Publication number Publication date
WO2003011008A2 (en) 2003-02-13
EP1421170A2 (en) 2004-05-26
JP2005500340A (en) 2005-01-06
CA2455843A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2001083729A3 (en) Vectors for ocular transduction and use thereof for genetic therapy
WO2003013437A3 (en) Compositions and methods for the prevention and treatment of huntington's disease
AU2001292881A1 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2001048190A8 (en) Therapeutic uses of lna-modified oligonucleotides
WO2005079195A3 (en) Pyrazolopyridines and analogs thereof
AU3755900A (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2002002624A3 (en) B7-like molecules and uses thereof
MXPA03002413A (en) B7-like molecules and uses thereof.
WO2004014312A3 (en) Small-mer compositions and methods of use
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
EP1417216A4 (en) ANTISENSE MODULATION OF BCL2-ASSOCIATED X-PROTEIN EXPRESSION
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
WO2004039957A3 (en) Inhibition of gene expression using rna interfering agents
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
DE69732029D1 (en) DNA-Containing VACCINES
WO2003059376A8 (en) The use of il6r/il6 chimera in nerve cell regeneration
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
WO2003011008A3 (en) Therapeutic delivery compositions and methods of use thereof
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
AU2002341207A1 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
AU2002223402A1 (en) A novel gene therapy agent for haemophilia b and its preparation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002329679

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2455843

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003516253

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002765919

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002765919

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10485610

Country of ref document: US